China’s Regulators Accept Jiuyuan Gene’s Application For Ozempic Biosimilar

Jiuyuan Gene scored a country-wide first as China’s regulator accepted its marketing application for a semaglutide biosimilar in type 2 diabetes that will be marketed as Jiyoutai.